Engineering Functionality-Optimized Fully Human B7-H3 CAR T Cells for Enhanced Solid Tumor Therapy
Bajgain, P.; Feng, Y.; Puebla, M.; Tian, M.; Hsu, K.-S.; Lee, J.; Yu, G.; Yang, L.; Seaman, S.; Hilton, M. B.; Morris, K.; Borchin, N.; Tran, J. D.; Metcalfe, R. D.; Cronk, J.; Khan, J.; Nellan, A.; Kaplan, R. N.; St. Croix, B.
Show abstract
B7-H3 is a cell surface protein overexpressed in many solid tumors and an attractive target for chimeric antigen receptor (CAR) T cell therapy. The most clinically advanced B7-H3 CARs are derived from murine monoclonal antibodies (mAbs) 376.96 and MGA271, which are now in phase 1/11 trials. However, non-human mAb sequences can provoke immune responses, leading to CAR T-cell rejection and therapeutic failure. Although scFv humanization reduces this risk, residual foreign residues within the variable domains remain. To overcome this limitation, we used in vitro phage display to generate fully human B7-H3-specific scFvs for CAR design. In pancreatic cancer, neuroblastoma, and glioblastoma xenograft models, CAR T cells incorporating the lead human binder Y111 were well tolerated and demonstrated superior antitumor activity compared with 376.96- and MGA271-based CARs. Y111 CAR treatment induced complete responses, tumor rejection, and significant survival benefits, identifying Y111 as a promising fully human B7-H3 CAR for solid tumors.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Pooled screening for CAR function identifies novel IL13Rα2-targeted CARs for treatment of glioblastoma 97%
- Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies 97%
- GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma 96%
Similar papers in this journal
- Pre-conditioning Modifies the Tumor Microenvironment to Enhance Solid Tumor CAR T Cell Efficacy and Endogenous Immunity 97%
- A functional screening platform for engineering chimeric antigen receptors with reduced on-target, off-tumour activation 96%
- Armored Bicistronic CAR T Cells with Dominant-negative TGF-β Receptor II to Overcome Resistance in Glioblastoma. 95%
Similar papers in this journal
- PTPRZ1-targeting RNA CAR-T cells exert antigen-specific and bystander antitumor activity in glioblastoma 96%
- Targeting macrophages with CAR-T cells delays solid tumor progression and enhances anti-tumor immunity 95%
- The CCL17-CCR4 axis is critical for mutant STAT6-mediated microenvironmental remodelling and therapeutic resistance in Relapsed/Refractory Diffuse Large B Cell Lymphoma 95%
Similar papers in this journal
- Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting 96%
- Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor resistant HER2-positive breast cancer 96%
- Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.